Brief: Impel Pharmaceuticals Announces Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
24/03/2023 12:38
March 24 (Reuters) - Impel Pharmaceuticals Inc IMPL.O :
* IMPEL PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL
YEAR
2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
* PROJECTS TRUDHESA WILL DELIVER PRESCRIPTIONS WITHIN RANGE
OF
80,000 - 110,000 TRX FOR FULL YEAR 2023
* QTRLY LOSS PER SHARE $0.97
* NET PRODUCT REVENUE INCREASED 62% TO $5 MILLION IN Q4
VERSUS Q3
2022
* Q4 EARNINGS PER SHARE VIEW $-1.11 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX2zhYmp
Further company coverage: IMPL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on IPI Legacy Liquidation Co
See all newsBrief: Impel Pharmaceuticals- On Dec 19, 2023, Co And Impel NeuroPharma Australia Commenced Voluntary Chapter 11 Proceedings
Brief: Impel Pharmaceuticals Says On Dec 1 Michael Kalb Gave Notice Of Resignation From Position As CFO With Last Day To Be December 31
U.S. STOCKS ON THE MOVE-iRobot Corp, Faraday Future, Fisker
U.S. STOCKS ON THE MOVE-iRobot Corp, Fisker Inc, International Seaways Inc
Brief: Impel Pharmaceuticals Receives Delisting Notice From Nasdaq